Pancreatic Cancer Trial, Recruiting NCT05058846 Sponsor: University of California, San Francisco Condition: Pancreatic Cancer
Back to Pancreatic Cancer

Pancreatic Cancer Trial, Recruiting

NCT05058846
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Group I (no strong family history of pancreatic cancer):

  • People who have a documented harmful or likely harmful genetic mutation in one of these genes: BRCA1, BRCA2, ATM, or PALB2
  • People who do not have a close family history of pancreatic cancer — meaning no first-degree relatives (such as a parent or sibling) or second-degree relatives (such as an aunt, uncle, or grandparent) have had pancreatic cancer
  • People aged 50 or older at the time of joining the study

Group II (with a strong family history of pancreatic cancer):

  • People who have a documented harmful or likely harmful genetic mutation in one of these genes: BRCA1, BRCA2, ATM, or PALB2
  • People who have at least one first-degree or second-degree relative who has had pancreatic cancer
  • People aged 18 or older at the time of joining the study

All participants:

  • People who are able to give informed consent and are willing and able to follow the study procedures
  • People who can read and speak English

Who may not be able to join:

  • People who have previously had, or currently have, pancreatic cancer
  • People who are currently pregnant, as the effects of MRI scans on a developing baby are not yet fully known

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Pamela N Munster, MD, University of California, San Francisco

Phone: (415) 353-8337

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
20 January 2022
Est. completion
31 January 2032

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Proportion of participants with of abnormal magnetic resonance imaging (MRI) findings

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov